ImmunityBio 3Q 2026: Revenue $48.84M, EPS ($0.18) — 10-Q Summary
ImmunityBio reported 3Q 2026 revenue of $48.84M, up 52% YoY, driven by ANKTIVA sales. Net loss widened to $50.45M due to higher R&D and SG&A costs. FDA approved ANKTIVA for additional use. IBRX
How this was made
The 30-second read
Why it matters
The combination of strong top‑line growth and a new FDA indication provides a clear catalyst that could drive the stock higher in the short term.
Market read
Micro‑cap biotech news with material regulatory approval; likely to affect IBRX and peers in the oncology space.
What to watch
Potential reimbursement challenges and competition from other NMIBC treatments.
Background
ImmunityBio (IBRX) filed its Q3 2026 10‑Q, highlighting a 52% YoY revenue increase driven by ANKTIVA sales and announcing FDA approval for ANKTIVA with BCG in a specific bladder cancer indication.
Ticker impact
ImmunityBio reported Q3 2026 results with 52% revenue growth and FDA approval of ANKTIVA for NMIBC.
upside pressure as market prices in the regulatory approval and revenue beat
The 10‑Q is the first public disclosure of the approval and financials, a material catalyst for a micro‑cap biotech.
Market effects
Boosts confidence in biotech firms with FDA approvals, may lift peer NMIBC therapy stocks.
Positive for US biotech sector; limited broader market effect.
Limited to biotech investors, no global macro impact.
Counterpoint
If the approval faces post‑market regulatory scrutiny, the rally could be short‑lived.
Key entities
- companyImmunityBio, Inc.
Biotech company reporting Q3 results and receiving FDA approval.
- regulatorFDA
Approved ANKTIVA for BCG‑unresponsive NMIBC.
